Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Direct Oral Anticoagulants Vs. Enoxaparin for Prevention of Venous Thromboembolism Following Orthopedic Surgery: A Dose-Response Meta-analysis.

Boyd RA, DiCarlo L, Mandema JW.

Clin Transl Sci. 2017 Jul;10(4):260-270. doi: 10.1111/cts.12471. Epub 2017 May 23.

2.

Short-Term Efficacy Reliably Predicts Long-Term Clinical Benefit in Rheumatoid Arthritis Clinical Trials as Demonstrated by Model-Based Meta-Analysis.

Wang Y, Zhu R, Xiao J, Davis JC Jr, Mandema JW, Jin JY, Tang MT.

J Clin Pharmacol. 2016 Jul;56(7):835-44. doi: 10.1002/jcph.668. Epub 2015 Dec 31.

3.

A model-based dose-response meta-analysis of ocular hypotensive agents as a drug development tool to evaluate new therapies in glaucoma.

Raber S, Mandema JW, Li H, Nickens DJ.

J Ocul Pharmacol Ther. 2015 May;31(4):189-97. doi: 10.1089/jop.2014.0106. Epub 2015 Feb 25. Review.

PMID:
25714918
4.

Time course of bone mineral density changes with denosumab compared with other drugs in postmenopausal osteoporosis: a dose-response-based meta-analysis.

Mandema JW, Zheng J, Libanati C, Perez Ruixo JJ.

J Clin Endocrinol Metab. 2014 Oct;99(10):3746-55. doi: 10.1210/jc.2013-3795. Epub 2014 Jun 10.

PMID:
24915115
6.

An adaptive-design dose-ranging study of PD 0348292, an oral factor Xa inhibitor, for thromboprophylaxis after total knee replacement surgery.

Cohen AT, Boyd RA, Mandema JW, Dicarlo L, Pak R; A5571010 Investigators.

J Thromb Haemost. 2013 Aug;11(8):1503-10. doi: 10.1111/jth.12328. Erratum in: J Thromb Haemost. 2018 Dec;16(12):2541.

7.

Model-based drug development: a rational approach to efficiently accelerate drug development.

Milligan PA, Brown MJ, Marchant B, Martin SW, van der Graaf PH, Benson N, Nucci G, Nichols DJ, Boyd RA, Mandema JW, Krishnaswami S, Zwillich S, Gruben D, Anziano RJ, Stock TC, Lalonde RL.

Clin Pharmacol Ther. 2013 Jun;93(6):502-14. doi: 10.1038/clpt.2013.54. Epub 2013 Mar 14.

PMID:
23588322
8.

Model-based meta-analysis for comparative efficacy and safety: application in drug development and beyond.

Mandema JW, Gibbs M, Boyd RA, Wada DR, Pfister M.

Clin Pharmacol Ther. 2011 Dec;90(6):766-9. doi: 10.1038/clpt.2011.242.

PMID:
22089340
9.

Therapeutic index of anticoagulants for prevention of venous thromboembolism following orthopedic surgery: a dose-response meta-analysis.

Mandema JW, Boyd RA, DiCarlo LA.

Clin Pharmacol Ther. 2011 Dec;90(6):820-7. doi: 10.1038/clpt.2011.232. Epub 2011 Nov 2.

PMID:
22048231
10.

A dose-response meta-analysis for quantifying relative efficacy of biologics in rheumatoid arthritis.

Mandema JW, Salinger DH, Baumgartner SW, Gibbs MA.

Clin Pharmacol Ther. 2011 Dec;90(6):828-35. doi: 10.1038/clpt.2011.256. Epub 2011 Nov 2.

PMID:
22048227
11.

Discovery of novel hepatoselective HMG-CoA reductase inhibitors for treating hypercholesterolemia: a bench-to-bedside case study on tissue selective drug distribution.

Pfefferkorn JA, Litchfield J, Hutchings R, Cheng XM, Larsen SD, Auerbach B, Bush MR, Lee C, Erasga N, Bowles DM, Boyles DC, Lu G, Sekerke C, Askew V, Hanselman JC, Dillon L, Lin Z, Robertson A, Olsen K, Boustany C, Atkinson K, Goosen TC, Sahasrabudhe V, Chupka J, Duignan DB, Feng B, Scialis R, Kimoto E, Bi YA, Lai Y, El-Kattan A, Bakker-Arkema R, Barclay P, Kindt E, Le V, Mandema JW, Milad M, Tait BD, Kennedy R, Trivedi BK, Kowala M.

Bioorg Med Chem Lett. 2011 May 1;21(9):2725-31. doi: 10.1016/j.bmcl.2010.11.103. Epub 2010 Nov 26.

PMID:
21183342
12.

Model-based development of gemcabene, a new lipid-altering agent.

Mandema JW, Hermann D, Wang W, Sheiner T, Milad M, Bakker-Arkema R, Hartman D.

AAPS J. 2005 Oct 7;7(3):E513-22. Review.

14.
15.

Pharmacokinetics of melagatran and the effect on ex vivo coagulation time in orthopaedic surgery patients receiving subcutaneous melagatran and oral ximelagatran: a population model analysis.

Eriksson UG, Mandema JW, Karlsson MO, Frison L, Gisleskog PO, Wählby U, Hamrén B, Gustafsson D, Eriksson BI.

Clin Pharmacokinet. 2003;42(7):687-701.

PMID:
12844328
16.

Quantification of pharmacodynamic interactions between dexmedetomidine and midazolam in the rat.

Bol CJ, Vogelaar JP, Tang JP, Mandema JW.

J Pharmacol Exp Ther. 2000 Jul;294(1):347-55.

PMID:
10871332
17.

Anesthetic profile of dexmedetomidine identified by stimulus-response and continuous measurements in rats.

Bol CJ, Vogelaar JP, Mandema JW.

J Pharmacol Exp Ther. 1999 Oct;291(1):153-60.

PMID:
10490899
18.

Characterization of the pharmacodynamic interaction between parent drug and active metabolite in vivo: midazolam and alpha-OH-midazolam.

Tuk B, van Oostenbruggen MF, Herben VM, Mandema JW, Danhof M.

J Pharmacol Exp Ther. 1999 May;289(2):1067-74.

PMID:
10215689
19.

Pharmacokinetic-pharmacodynamic modeling of the anticonvulsant and electroencephalogram effects of phenytoin in rats.

Della Paschoa OE, Mandema JW, Voskuyl RA, Danhof M.

J Pharmacol Exp Ther. 1998 Feb;284(2):460-6.

PMID:
9454785
20.
21.

Relevance of arteriovenous concentration differences in pharmacokinetic-pharmacodynamic modeling of midazolam.

Tuk B, Herben VM, Mandema JW, Danhof M.

J Pharmacol Exp Ther. 1998 Jan;284(1):202-7.

PMID:
9435179
22.

Determination of dexmedetomidine in rat plasma by a sensitive [3H]clonidine radioreceptor assay.

Bol CJ, IJzerman AP, Danhof M, Mandema JW.

J Pharm Sci. 1997 Jul;86(7):822-6.

PMID:
9232523
23.

The impact of arteriovenous concentration differences on pharmacodynamic parameter estimates.

Tuk B, Danhof M, Mandema JW.

J Pharmacokinet Biopharm. 1997 Feb;25(1):39-62.

PMID:
9353693
24.

Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development.

Minto CF, Schnider TW, Egan TD, Youngs E, Lemmens HJ, Gambus PL, Billard V, Hoke JF, Moore KH, Hermann DJ, Muir KT, Mandema JW, Shafer SL.

Anesthesiology. 1997 Jan;86(1):10-23.

PMID:
9009935
25.

Population pharmacodynamic model for ketorolac analgesia.

Mandema JW, Stanski DR.

Clin Pharmacol Ther. 1996 Dec;60(6):619-35.

PMID:
8988064
26.

Characterization and validation of a pharmacokinetic model for controlled-release oxycodone.

Mandema JW, Kaiko RF, Oshlack B, Reder RF, Stanski DR.

Br J Clin Pharmacol. 1996 Dec;42(6):747-56.

27.

Pharmacokinetic/pharmacodynamic relationship of benzodiazepines in the direct cortical stimulation model of anticonvulsant effect.

Hoogerkamp A, Arends RH, Bomers AM, Mandema JW, Voskuyl RA, Danhof M.

J Pharmacol Exp Ther. 1996 Nov;279(2):803-12.

PMID:
8930187
28.

Population pharmacodynamic modeling and covariate detection for central neural blockade.

Schnider TW, Minto CF, Bruckert H, Mandema JW.

Anesthesiology. 1996 Sep;85(3):502-12.

PMID:
8853080
29.

Thiopental uncouples hippocampal and cortical synchronized electroencephalographic activity.

MacIver MB, Mandema JW, Stanski DR, Bland BH.

Anesthesiology. 1996 Jun;84(6):1411-24.

PMID:
8669683
30.

High-performance liquid chromatographic assay of propofol in human and rat plasma and fourteen rat tissues using electrochemical detection.

Dowrie RH, Ebling WF, Mandema JW, Stanski DR.

J Chromatogr B Biomed Appl. 1996 Apr 12;678(2):279-88.

PMID:
8738032
31.

Population pharmacokinetics of didanosine in patients with human immunodeficiency virus infection.

Harb GE, Mandema JW, Delahunty T, Benowitz NB, Coleman R, Sheiner LB, Jacobson MA.

J Infect Dis. 1996 Jan;173(1):273. No abstract available.

PMID:
8537676
32.
33.

Application of intracerebral microdialysis to study regional distribution kinetics of drugs in rat brain.

de Lange EC, Bouw MR, Mandema JW, Danhof M, de Boer AG, Breimer DD.

Br J Pharmacol. 1995 Nov;116(5):2538-44.

34.

Pharmacodynamic interaction between midazolam and a low dose of ethanol in vivo.

Hoyo-Vadillo C, Mandema JW, Danhof M.

Life Sci. 1995;57(4):325-33.

PMID:
7603305
35.

The pharmacokinetics of propofol in children using three different data analysis approaches.

Kataria BK, Ved SA, Nicodemus HF, Hoy GR, Lea D, Dubois MY, Mandema JW, Shafer SL.

Anesthesiology. 1994 Jan;80(1):104-22.

PMID:
8291699
36.

A comparison of the concentration-effect relationships of midazolam for EEG-derived parameters and saccadic peak velocity.

Van Steveninck AL, Mandema JW, Tuk B, Van Dijk JG, Schoemaker HC, Danhof M, Cohen AF.

Br J Clin Pharmacol. 1993 Aug;36(2):109-15.

37.

Pharmacokinetic-pharmacodynamic modelling in pre-clinical investigations: principles and perspectives.

Danhof M, Mandema JW, Hoogerkamp A, Mathôt RA.

Eur J Drug Metab Pharmacokinet. 1993 Jan-Mar;18(1):41-7. Review.

PMID:
8335038
38.

Evaluation of Bayesian estimation in comparison to NONMEM for population pharmacokinetic data analysis: application to pefloxacin in intensive care unit patients.

Bruno R, Iliadis MC, Lacarelle B, Cosson V, Mandema JW, Le Roux Y, Montay G, Durand A, Ballereau M, Alasia M, et al.

J Pharmacokinet Biopharm. 1992 Dec;20(6):653-69.

PMID:
1302767
39.

Modelling of the pharmacodynamics and pharmacodynamic interactions of CNS active drugs.

Danhof M, Mandema JW.

Int J Clin Pharmacol Ther Toxicol. 1992 Nov;30(11):516-9. Review.

PMID:
1490817
40.

Building population pharmacokinetic--pharmacodynamic models. I. Models for covariate effects.

Mandema JW, Verotta D, Sheiner LB.

J Pharmacokinet Biopharm. 1992 Oct;20(5):511-28.

PMID:
1287200
41.
42.

Pharmacokinetic-EEG effect relationship of midazolam in aging BN/BiRij rats.

Hovinga S, Stijnen AM, Langemeijer MW, Mandema JW, van Bezooijen CF, Danhof M.

Br J Pharmacol. 1992 Sep;107(1):171-7.

43.

Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite alpha-hydroxymidazolam in healthy volunteers.

Mandema JW, Tuk B, van Steveninck AL, Breimer DD, Cohen AF, Danhof M.

Clin Pharmacol Ther. 1992 Jun;51(6):715-28.

PMID:
1611810
44.

Modeling of the effect site equilibration kinetics and pharmacodynamics of racemic baclofen and its enantiomers using quantitative EEG effect measures.

Mandema JW, Heijligers-Feijen CD, Tukker E, De Boer AG, Danhof M.

J Pharmacol Exp Ther. 1992 Apr;261(1):88-95.

PMID:
1560387
45.

In vivo modeling of the pharmacodynamic interaction between benzodiazepines which differ in intrinsic efficacy.

Mandema JW, Kuck MT, Danhof M.

J Pharmacol Exp Ther. 1992 Apr;261(1):56-61.

PMID:
1560385
46.
47.
48.

Estimation of amobarbital plasma-effect site equilibration kinetics. Relevance of polyexponential conductance functions.

Mandema JW, Veng-Pedersen P, Danhof M.

J Pharmacokinet Biopharm. 1991 Dec;19(6):617-34.

PMID:
1815044
49.

A population analysis of the pharmacokinetics and pharmacodynamics of midazolam in the rat.

Aarons L, Mandema JW, Danhof M.

J Pharmacokinet Biopharm. 1991 Oct;19(5):485-96.

PMID:
1783988
50.

Biophase equilibration times.

Veng-Pedersen P, Mandema JW, Danhof M.

J Pharm Sci. 1991 Sep;80(9):881-6.

PMID:
1800713

Supplemental Content

Loading ...
Support Center